Podoplanin expression in basal and myoepithelial cells: utility and potential pitfalls

Author(s): Kanner WA, Galgano MT, Atkins KA

Abstract

Podoplanin, D2-40, is often used for highlighting lymphatics. However, it has been described in a variety of normal and neoplastic tissues. We evaluated the expression of D2-40 in breast, salivary gland, skin, and mucosa, all organs rich in myoepithelial cells and basal cells. This study assessed the utility of using D2-40 to highlight basal/myoepithelial cells and to identify potential pitfalls in misinterpretation of lymphatic invasion. Our results showed that myoepithelial cells in breast and salivary gland and basal cells in prostate consistently demonstrate D2-40 immunoreactivity, but typically less intensely than lymphatics. Cutaneous and mucosal-based basal cells also have D2-40 expression, but often in a patchy, focal manner. In addition, many salivary gland tumors and squamous cell carcinomas had strong D2-40 expression, sometimes making distinction of lymphatics versus tumor edge staining difficult. D2-40 is excellent for assessing lymphatic invasion in breast, prostate, and cervix as long as the pathologist is aware of the expression in myoepithelial cells/basal cells to avoid misinterpretation of ductal carcinoma in situ or normal prostate glands or tumor stroma retraction as tumor lymphatic invasion. Given the patchy positivity in basal cells of skin and mucosa and the reactivity in squamous cell carcinoma, D2-40 was not helpful in assessing for microinvasion of squamous cell carcinoma.

Similar Articles

Overexpression of podoplanin in oral cancer and its association with poor clinical outcome

Author(s): Yuan P, Temam S, El-Naggar A, Zhou X, Liu DD, et al.

Podoplanin expression in the development and progression of laryngeal squamous cell carcinomas

Author(s): Rodrigo JP, García-Carracedo D, González MV, Mancebo G, Fresno MF, et al.

The role of podoplanin in tumor progression and metastasis

Author(s): Raica M, Cimpean AM, Ribatti D

Genetics/epigenetics of oral premalignancy: current status and future research

Author(s): Lingen MW, Pinto A, Mendes RA, Franchini R, Czerninski R, et al.

Overexpression of podoplanin in oral cancer and its association with poor clinical outcome

Author(s): Yuan P, Temam S, El-Naggar A, Zhou X, Liu DD, et al.

The significance of podoplanin expression in human inflamed gingiva

Author(s): Miyazaki Y, Okamoto E, González-Alva P, Hayashi J, Ishige T, et al.

Podoplanin expression in odontomas: clinicopathological study and immunohistochemical analysis of 86 cases

Author(s): González-Alva P, Inoue H, Miyazaki Y, Tsuchiya H, Noguchi Y, et al.

Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy

Author(s): Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, et al.

Podoplanin expression in oral leukoplakia: tumorigenic role

Author(s): De Vicente JC, Rodrigo JP, Rodriguez-Santamarta T, Lequerica-Fernández P, Allonca E, et al.

Overexpression of podoplanin in oral cancer and its association with poor clinical outcome

Author(s): Yuan P, Temam S, El-Naggar A, Zhou X, Liu DD, et al.

The potential role of podoplanin in tumour invasion

Author(s): Wicki A, Christofori G

The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis

Author(s): Kunita A, Kashima TG, Morishita Y, Fukayama M, Kato Y, et al.

Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition

Author(s): Martín-Villar E, Megías D, Castel S, Yurrita MM, Vilaró S, et al.

Podoplanin, a novel marker of tumor-initiating cells in human squamous cell carcinoma A431

Author(s): Atsumi N, Ishii G, Kojima M, Sanada M, Fujii S, et al.

The potential role of podoplanin in tumour invasion

Author(s): Wicki A, Christofori G